Back to results
US 5,707,821 AGranted
Identification of phospholipase A2 inhibitors in A.beta. peptide-mediated neurodegenerative disease
AssigneeAthena Neurosciences, Inc.
InventorsRussell E. Rydel, Michael S. Dappen
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions for treating neurodegeneration in mammalian cells by administering a phospholipase A2 inhibitor.
Claims7
A method for identifying active agents which inhibit neuronal degeneration induced by A.beta. peptide, comprising
- administering an agent to a cell population consisting essentially of neurons or cells from neuronal cell lines, wherein said cell population is exposed to an amount of pathogenic amyloid .beta.("A.beta.") peptide that induces neuronal degeneration in the cell population,
- determining whether the agent produces a detectable reduction in the amount and/or rate of neuronal degeneration in the cell population;
- and
- determining whether the agent produces inhibition of phospholipase A2 "PLA.sub.2 " activity;
- whereby if the agent produces inhibition of PLA.sub.2 activity and inhibits neuronal degeneration, the agent is thereby identified as an active agent.
2 more elements
Dependencies are inferred from the claim text.